5 recruiting, 3 active not recruiting, 2 completed. 10 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Recruiting 5, Active not recruiting 3, Completed 2 |
Follow Psilocybin: new trials by email Literature Review of Psilocybin trials Research Report on Psilocybin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression Psilocybin - Major Depression | Phase 3 | Recruiting | VA Office of Research and Development | 240 | 2026-08-03 | 2026-10-23 |
| Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms Psilocybin (high dose), Psilocybin (low dose) - Alcohol Use Disorder, Depressive Sympotoms | Phase 3 | Recruiting | Centre Hospitalier Universitaire de Nīmes | 172 | 2026-06-30 | 2026-07-01 |
| Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder Psilocybin, Structured Integrated Reframing Therapy (SIRT), Selective Serotonin Reuptake Inhibitor (SSRI) - Major Depressive Disorder, Post-Traumatic Stress Disorder (PTSD) | Phase 3 | Recruiting | Khyber Medical University Peshawar | 60 | 2026-04-01 | 2026-07-14 |
| Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT) Psilocybin, Placebo - Psychological Distress | Phase 3 | Recruiting | Bruyère Health Research Institute. | 120 | 2026-01-28 | 2026-07-10 |
| The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder Psilocybin - Major Depressive Disorder | Phase 3 | Recruiting | Sharmin Ghaznavi | 20 | 2024-09-10 | 2026-08-13 |
| Psilocybin-Assisted Therapy in Treatment-Resistant Depression psilocybin - Refractory Depression, Treatment Resistant Depression | Phase 3 | Active not recruiting | University of North Carolina, Chapel Hill | 20 | 2024-04-19 | 2026-05-06 |
| Psilocybin for Major Depressive Disorder (MDD) Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg - Depressive Disorder, Major | Phase 3 | Active not recruiting | Usona Institute | 238 | 2024-03-13 | 2026-10-21 |
| Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD Psilocybin - Treatment Resistant Depression | Phase 3 | Active not recruiting | COMPASS Pathways | 572 | 2023-02-14 | 2026-08-10 |
| Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD Psilocybin - Treatment Resistant Depression | Phase 3 | Completed | COMPASS Pathways | 258 | 2023-01-24 | 2026-08-10 |
| Frontline Clinician Psilocybin Study Psilocybin (Usona Institute), Active placebo - Burnout, Caregiver, Burnout, Professional | Phase 3 | Completed | University of Washington | 30 | 2022-03-03 | 2025-03-18 |
Depression (4) · Depressive Disorder, Major (4) · Depressive Disorder, Treatment-Resistant (3) · Stress Disorders, Post-Traumatic (3) · Alcoholism (1) · Burnout, Professional (1) · COVID-19 (1) · Caregiver Burden (1) · Wounds and Injuries (1)
COMPASS Pathways (2) · Bruyère Health Research Institute. (1) · Centre Hospitalier Universitaire de Nīmes (1) · Khyber Medical University Peshawar (1) · Sharmin Ghaznavi (1) · University of North Carolina, Chapel Hill (1) · University of Washington (1) · Usona Institute (1) · VA Office of Research and Development (1)
United States (7) · Canada (2) · France (2) · Czechia (1) · Denmark (1) · Germany (1) · Ireland (1) · Netherlands (1) · Pakistan (1) · Poland (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Amandine Luquiens (1) · Anthony Back, MD (1) · Charles Raison, MD (1) · Dr Inayat Shah, PhD* (1) · Dr Omer Malik, PhD (1) · Lori Lynne Davis, MD AB (1) · Naveeda Sarwar, PhD (1) · Robert K McClure, MD (1) · Sharmin Ghaznavi, M.D., Ph.D. (1)
2025 (1), I01RD001520 (1)